New hope for stubborn eye disease: arthritis drug shows promise
NCT ID NCT05651880
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests baricitinib, a drug used for arthritis, in 33 adults with a type of eye inflammation (uveitis) that hasn't improved with other treatments. The goal is to see if it can stop the inflammation completely after 6 months. Participants must stop their current medications before starting baricitinib, but may need long-term treatment to keep the disease under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACTIVE NON-ANTERIOR NON-INFECTIOUS UVEITIS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de ROUEN
Rouen, 76031, France
Contact Email: •••••@•••••
Contact